Document is current
Any future updates will be listed below
-
Authors
Leucht, Stefan https://orcid.org/0000-0002-4934-4352
Siafis, Spyridon https://orcid.org/0000-0001-8264-2039
McGrath, John J. https://orcid.org/0000-0002-4792-6068
McGorry, Patrick
Howes, Oliver D.
Tamminga, Carol
Carr, Richard
Bighelli, Irene
Schneider-Thoma, Johannes
Priller, Josef
Davis, John M. https://orcid.org/0000-0003-3963-1654
- License Information
-
More Information
Article History
Accepted: 23 October 2025
First Online: 27 November 2025
Competing interests
: In the last 3 years, S.L. has received honoraria as an adviser and/or for lectures and/or for educational material from Alkermes, Angelini, Apsen, Eisai, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Merck Sharp and Dohme, Mitsubishi, Neurotorium, NovoNordisk, Otsuka, Recordati, Roche, Rovi, Sanofi Aventis, and TEVA. C.T. is on the Scientific Advisory Board for Karuna, owns stock and is an adviser for KyNexis, and she reviews for the National Institute of Mental Health. O.D.H. has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Janssen, Karuna, Lundbeck, Merck, Neurocrine, Ontrack/Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi, and Viatris/Mylan. He was previously a part-time employee of Lundbeck A/v. O.D.H. has a patent for the use of dopaminergic imaging. J.P. has a patent on EPO variants and is a member of the SINAPPS2 TSC. All other authors declare no competing interests.
